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ABSTRACT
Background: Small nucleolar RNAs (snoRNAs) are small non-coding RNA sequences whose most studied
function is ribosome biogenesis. The altered expression of snoRNA is observed in tumoral processes such
as breast cancer and multiple myeloma. However, we have not found any references to snoRNAs in oral
squamous cell carcinomas (OSCC) in the literature at the time this article was written.
Material and methods: We have analyzed snoRNA expression in frozen OSCC tissue samples and have
compared them to healthy controls. RNA was extracted from a total of eight OSCC samples and eight con-
trol samples, measuring the differential expression of small RNAs with the AffymetrixVR miRNA 4.1 Array
Plate microarray platform.
Results: Results were analyzed using the Transcriptome Analysis Console 3.0 (TAC) software. We obtained
a total of 16 deregulated snoRNAs of which one was over expressed and 15 were under expressed.
SnoRNAs expression was altered in OSCC and could serve as a diagnostic marker.
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SnoRNAs (small nuclear RNAs) are a large class of non-coding RNA
found, in sequences of eukaryotic cells. The main functions under
study in this type of small non-coding RNAs is ribosome biogen-
esis, more specifically, the components of ribonucleoprotein com-
plexes (snoRNP)1. snoRNAs are divided into two groups, C/B and
H/ACA box, which differ in terms of characteristics and structure,
as well as other protein union points and the chemical modifica-
tions they catalyze2.
The function of the snoRNA C/D and H/ACA box is developed
in preribosomal RNA, modifying nucleotides at specific locations.
The members of the C/D box are involved in 2’-O-methilation and
those of the H/ACA box in pseudouridylation.
New snoRNAs are identified through ultrasequencing and
immunoprecipitation by the union of RNA to certain proteins,
although the lack of association of some snoRNAs and ribonucleic
complexes in the reviewed studies lead us to believe that the
regulatory functions they develop, may differ from those involved
in ribosomal biogenesis. Some studies suggest that snoRNAs can
also participate in the regulation of alternative splicing and post-
transcriptional modifications of messenger RNA3.
Therefore, alterations in the expression of these RNAs can affect
several vital and pathological processes, becoming a target for the
treatment and diagnosis of human neurodegenerative, onco-
logical, or viral pathologies4. The altered expression of snoRNAs
has been observed in cancer processes such as breast cancer and
multiple myeloma5,6. Specifically, the increased expression of
ACA11 seems to produce resistance to chemotherapy and
increased proliferation of multiple myeloma cell lines5.
In our bibliographic search, we found no references of snoRNA
expression in oral squamous cell carcinomas (OSCC). OSCC is the
most frequent malignancy of the oral cavity and the prognosis of
OSCC patients has not improved in the past years, despite the
advances in the biological and technological knowledge7. Only a
fraction of the patients exposed to risk factors (tobacco, alcohol,
and human papilloma virus) develops OSCC8. This suggests that
there are other factors, known or unknown, that we are not con-
sidering in oral cancer tumorigenesis.
Due to this need to continue to increase our knowledge on
OSCC and thus improve the survival of patients, our project seeks
to determine the expression of snoRNA in samples of frozen OSCC




We selected OSCC samples from the buccal mucosa, the soft
palate, the retromolar area, the tongue, and the floor of the
mouth, all of which had been extracted by the Maxillofacial
Surgery Unit of Complejo Hospitalario Universitario de Santiago
de Compostela (Santiago Teaching Hospital), which amounted to
eight cases that had been preserved at 80 C at the hospital’s
biobank (SERGAS), from 1998 to 2015. The same service also
obtained eight control samples of keratinized gums, collected in
2015 from the patients that visited the service for the extraction
of their third molar.
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All the samples were stored at the Santiago de Compostela
Biobank (SERGAS). Optimal cutting temperature freezing cuts were
developed on each sample, 14 cuts in 14 micrometers.
This research has obtained the approval of the Clinical
Research Ethics Committee of Galicia Ref. 2015/132 (CEIC),
currently known as the “Comite Autonomica da Etica da
Investigacion” (CAEI). All procedures were carried out with the
adequate understanding and written consent of the subjects.
Total RNA extraction and microarray
Total RNA was extracted using the el mirVanaTM miRNA isolation
kit. The concentration of the samples was measured with
NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA) and their
integrity was assessed (RIN) using NanoChip 6000 and bioanalyzer.
Once total RNA was extracted, we used AffymetrixVR FlashTagTM
Biotin HSR RNA Labeling Kit to mark the samples. The microarray
platform we used was AffymetrixVR miRNA 4.1 array plate that con-
tained enough probes to identify 2578 human miRNAs and 1996
human snoRNAs and scaRNA (“small Cajal body-specific RNA”). The
analysis of the differential expressions was developed using the
software Transcriptome Analysis Computer 3.0 by Affymetrix (free
access). Last of all, deregulated snoRNAs were searched on the
snoRNA-LMBE-db data base (https://www-snorna.biotoul.fr/index.
php, December 2016). All methods were performed in accordance
with the relevant guidelines and regulations.
Statistical analysis
For the univariate description we used basic descriptive statistics:
mean, standard deviation, frequency, and percentage.
For the differential expression of snoRNAs, the Transcritpome
Analysis Console 4.0 (TAC) developed a univariate ANOVA analysis
selecting genes with a “fold change” of over ±2 and a p valueun-
der .05.
To perform the comparison between clinical features and
snoRNA expression, we have recoded the expression values in
semiquantitative variables, considering over expressed when the
expression was over the mean expression level and under
expressed when the expression was under the mean expression
level. The relationship between clinical and pathological parame-
ters and the expression of snoRNAs deregulated were calculated
using non-parametric statistics with U Mann Whitney test and
parametric chi-square test depending on the application
conditions.
Kaplan Meier analysis and the log-rank test were performed to
identify survival differences in OSCC patients. Differences were
considered statistically significant when p was less than .05.
Results
Descriptive analysis
The mean age of the eight cases was 60.75 years, with a range of
41–75 years. Of the eight cases, five were women (62.5%) and
three were men (37.5%). Of the eight primary intraoral tumors,
three were on the tongue (37.5%), two on the gum (25%), one1 in
the molar trigone area (12.5%), one in the floor of the mouth
(12.5%), and one in the buccal mucosa (12.5%). Two were stage II
at the time of surgery and six were stage IV. Of the eight cases,
two were smokers (25%), one was a former smoker (12.5%), and
five were nonsmokers (62.5%).The mean age of the controls was
37.75 years, with a range of 18–75 years. Of the eight controls, two
were women (25%), and six were men (75%). In the control group,
two were smokers (25%) the other six were nonsmokers (75%).
The mean concentration of total extracted RNA in the case
group was 1145.25 ng/mL and in the control group 785.33 ng/mL.
The mean RIN of the total extracted RNA in the case group
amounted to 8.275 and 8.15 in the control group.
SnoRNA differential expression in OSCC
A total of 16 snoRNAs presented a significantly different expres-
sion in case samples in contract with the control samples; 15 were
overexpressed and one was under expressed. Table 1 shows the
name of the deregulated snoRNAs with their fold change and p
values. Each snoRNA was searched on the snoRNA-LMBE-db data-
base, from which we collected information on each of their fami-
lies, their location, length in nucleotides, and function (Table 2).
Associations with clinical and pathological features
We examined the expression of each snoRNA with clinical features
and we have found that 14qII-22 have statistical significant differ-
ent expression between gender categories (p¼ .031). Women have
an average expression of 4.93 (SD¼ 0.95) whereas men have an
average of 3.32 (SD¼ 1.43). However, there were no significant
correlation of snoRNAs expression with other clinical features such
as age or tobacco consumption.
Further, we have analyzed the pathological prognostic parame-
ters in patients with OSCC and expression levels and results
showed that U28 low expression is correlated with a good differ-
entiation (p¼ .018). Three of the cases (75%) with low expression
had good differentiation versus one case with bad differentiation.
We have found no correlation between other pathological features
as localization, TNM stage radiotherapy or chemotherapy, and
snoRNA expression.
Survival analysis
The average of OSCC patient’s survival time was 50.17months
(CI 95%: 2.539–97.795). We performed Kaplan-Meier curves for
overall survival by comparing the patients with high and low
snoRNA expression. Those patients which ENSG000002645191,
ENSG00000263442, ENSG00000265325, ENSG00000265607,
ENSG00000266646, ENSG00000266755, ENSG00000207118, U8, and
U28 expression was under the mean expression level had a higher
survival time (74.47 versus 25.89months). Those patients which
U18A, 14qII-12 expression was over the mean expression level had
Table 1. Deregulated snoRNAs comparing the samples of the cases and the con-
trols, with their fold change and p values.
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a higher survival time. Although the differences were not statistic-
ally significant. Both patients who had died, had an expression of
mgh18S-121 and ACA17 under the mean expression level. On the
other hand, the expression of 14qII-22 of the same patients was
over the mean expression level, although these differences were
not statistically significant.
Discussion
The results of this study reveal that the expression of snoRNAs in
OSCC is different when compared to healthy tissue, which makes
them a possible diagnostic and prognostic markers in OSCC. The
information of each deregulated snoRNA was searched on the
snoRNA-LMBE-db database9. We have not found information
regarding the function or the possible targets for most of the
deregulated snoRNAs in this study. Abnormal expression of
snoRNA hasn't been studied in OSCC although it has been ana-
lyzed in different types of cancer such as leukemia10, colorectal11,
and pancreatic cancer12. In our revision of McManhon et al. we
found that they reported on the differential expression of
snoRNAs in different diseases including head and neck cancers,
finding SNORA71C, which belongs to the H/ACA family, to be
under expressed. Deregulated snoRNAs in our study did not match
the ones collected in this revision13.
Altered expression of non-coded RNAs in OSCC has been
studied with the purpose of finding diagnostic and prognostic
markers and therapeutic targets14. However, the results of this
research have been different and on occasions, contradictory15.
The interpretation of the data of deregulated snoRNAs requires
further research in the field, since small fragments of RNA have
been found in the C/D and H/ACA box with traditional blocking
function, similar to microRNAs and have been associated to
Argonaute 2 (AGO2). The Argonaute protein is necessary for RNAs,
such as microRNAs, to form the RISC complex, and thus induce
the silencing of messenger RNAs. Therefore, a series of microRNAs
that silence messenger RNAs and are originated from precursors
leading to the C/D or H/ACA boxes have been discovered. These
microRNAs match the snoRNAs, as for example, SNORD12b/HBII-
99B (miR-1259), SNORD126 (miR-1201), SNORA34/ACA34 (miR-
1291), SNORA81/HBI-61 (miR-1248), and SNORA36B/ACA36B (miR-
664)2. None of these snoRNAs have shown a deregulated expres-
sion in our study.
Considering the location of the deregulated snoRNAs in this
study, an alteration in the expression is expected to be caused by
mutations in the chromosomal regions. Upon review of the litera-
ture on alterations and chromosomal instability in OSCC, some
studies reveal that in chromosome 9, where ACA17 is located,
there are mutations in almost 70% of OSCC cases, affecting the
function of proteins such as p1616. Genetic alterations that affect
proteins in chromosome 11 have also been reported, such as
Cyclin D1, which has been broadly studied in tumor processes17.
We have used keratinized gum as the healthy control tissue
because there were OSCC samples from gum also, it is a location
that also can suffer OSCC, it is exposed to risk factors in a similar
way as the other parts of the oral cavity and it was the less inva-
sive manner to take the control of the healthy patients. In a
future, it would be better to use healthy samples of the same
type of tissue (buccal mucosa, soft palate, retromolar region,
tongue, and floor of the mouth) thus matching the location of the
OSCC samples.
Although the mean age of the cases group doubled the mean
age of the control group, we have found no references in the litera-
ture regarding the alteration of snoRNA expression in relation to age.
Our results have revealed different 14qII-22 expression levels
between males and females and also have found lower U28
expression levels in those cases with good differentiation.
Although we have found no references in literature that correlates
snoRNA expression and clinical features and prognosis, to verify
the usefulness of these snoRNAs as diagnostic and prognostic
markers in OSCC it is necessary to corroborate the results by
means of Quantitative reverse transcription -polymerase chain
reaction and study a larger sample size.
The results of our study are a first step in future research on
the role of snoRNAs in oral cancer.
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Table 2. Deregulated snoRNAs in OSCC specifying the type of snoRNA, the family they belong to, the chromosome in which they are located, the nucleotides form-
ing it and their function, known or unknown (?).
Name Family Location Length (nt) Function
ACA17 H/ACA box Chromosome 9 133 It is believed that pseudouridylation of
U4659, U4598, and U4937 waste and
the ribosomal subunit 28S rRNA
14q1-4 C/D box Chromosome 14, intronic sequence of MEG8 74 ?
14q11-12 C/D box Chromosome 14, intronic sequence of MEG8 74 ?
14q11-22 C/D box Chromosome 14, intronic sequence of MEG8 71 ?
U84 C/D box Chromosome 19, intronic sequence of BAT1 78 ?
mg18S-121 (Z17A) C/D box Chromosome 17, intronic sequence of RPL23A 72 Its function is to guide 2’O-ribose
methylation of 18S rARN U121.
U18A C/D box Chromosome 15, intronic sequence of
ribosomal protein RPL4
70 Its function is to guide 2’O-ribose
methylation of 28S rARN A1313
U8 C/D box Independent Transcription Unit 136 ?
U28 C/D box Chromosome 11, intronic sequence of gene U22 75 Methylation guide of 2’O-ribose in 18S
rARN C1391.
ENSG00000263442 C/D box Chromosome 6 78 ?
ENSG00000264591 C/D box Chromosome 6 78 ?
ENSG00000265325 C/D box Chromosome 6 78 ?
ENSG00000265607 C/D box Chromosome 6 78 ?
ENSG00000266646 C/D box Chromosome 6 78 ?
ENSG00000266755 C/D box Chromosome 6 78 ?
ENSG00000207118 C/D box Chromosome 11 87 ?
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